ALX1 and cancer: The levels of lnc-ALX1-2 and lnc-KLF17-1 distinguished responders from non-responders with high specificity and dropped after the surgical removal of the tumor, nevertheless, they were also detectable in 2 cancer-free controls (6.67%) suggesting that the release of these RNAs in plasma EVs is not always associated with the presence of cancer.